Hile Bio-Technology streamlines governance, shifts focus, reports profit surge

Shanghai Hile Bio-Technology has approved significant governance changes, including the abolition of the supervisory board, with its functions transferred to the board's audit committee. The company will also relocate its registered address to Shenggang Avenue and update its business scope, removing references to veterinary drug operations and clarifying its focus on medical devices and biological technology. These amendments will be submitted for shareholder approval.

In a concurrent development, Hile Bio-Technology released its 2025 semi-annual report, showing a 2.02% increase in operating revenue to CNY 109,776,927.64, and a notable 122.04% rise in total profit to CNY 36,596,574.60 compared to the previous year. Net profit attributable to shareholders increased by 20.56% to CNY 18,234,848.34. An investor briefing is scheduled for September 17, 2025, to discuss the financial results and strategic direction.